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HAM Kerstiens and PLP Brand
I4.l Summary
The multi-centre study which is described in this thesis was performed in patients with
obstructive airways disease, including both asthma and chronic obstructive pulmonary
disease (COPD). Asthma is a syndrome characterized by attacks of dyspnea or wheezing
and variable airways obstruction. The clinical hallmark is increased airways
responsiveness which in part reflects the underlying chronic inflammatory process.
COPD is a chronic disease with fixed airways obstruction and is closely related to
smoke inhalation. It is characterized by a progressive loss of lung function.
Epidemiological data point to a worldwide rise in mortality from COPD. Such a rise,
however, occurs in asthma as well, but not invariably in all countries, especially not in
the Netherlands for some ill-understood reason. Morbidity associated with asthma and
COPD is considerable: approximately 10-20oh of the Dutch population has the
characteristic respiratory symptoms.
Intermittent or not, both asthma and COPD cause chronic symptoms and lung function
abnormalities which in many cases elicit the use of medication, often for years on end.
Surprisingly, the majority of clinical trials to date have assessed only the short-term
efficacy of various drugs for obstructive airways disease.
In view of the ongoing high morbidity and mortality of obstructive airways disease, it is
important to firstly determine risk factors for the development and further progression of
the disorder, and secondly to try to influence these risk factors with either preventive
measures or treatment in order to improve the course and prognosis of the disease. For
asthma, prognosis is primarily related to the levels of airways obstruction and hyper-
responsiveness. In COPD, prognosis is primarily related to age and initial level of
airways obstruction, and next to smoking, airways hyperresponsiveness, and perhaps to
reversibility of obstruction. Hence, asthma and COPD share the presence of obstruction
and l.ryperresponsiveness as risk factors in disease prognosis.
In the present study two central hypotheses were tested:
L Treatment aimed at redressment of both common risk factors for progression of
disease, i.e. airways hyperresponsiveness (by an inhaled corticosteroid) and airways
obstruction (by a Br-agonist) compares favourably in long-term prognosis to
symptomatic treatment of airways obstruction alone (by a Br-agonist).
2. More vigorous bronchodilation with both an inhaled Br-agonist and an
anticholinergic offers long-term benefits in disease prognosis as compared to a Br-
agonist alone.
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The general methods of the study are described in chapter 2. It was designed as a
multi-centre randomized clinical trial with a follow-up of 3 years. Patients were
randomly assigned to one of three parallel treatment arms. From identical, blinded
metered dose inhalers, all patients received a f3r-agonist (terbutaline sulphate two puffs
of 250pg four times daily) with additionally in a second canister either:
1) a corticosteroid (beclomethasone dipropionate two puffs of 100pg four times daily)
2) an anticholinergic (ipratropium bromide two puffs of 20 prg four times daily)
3) a placebo (also two puffs four times daily).
Much effort was put into the standardization of lung function measurements and the
bronchial provocation tests. A three months feasibility study was found to be extremely
useful in eliminating minor problems from the study protocol.
Since the following factors are all characteristics of the disease at any given moment
and can therefore be considered possible confounders of a treatment effect, the
randomization was carefully stratifred for these factors and their influence on treatment
effects was subsequently analyzed. The disease characteristics stratilted for were:
airways obstruction, airways hyperresponsiveness, reversibility of airways obstruction,
age, gender, smoking habit, atopy, and prior use of inhaled corticosteroids. Stratification
was done by minimization method and resulted in well-balanced treatment groups for all
above factors and participating centre. It was performed on a personal computer by an
independent central 24 hour service telephone centre.
The 274 patients enroled into the study were divided into symptom-based diagnosis
groups using data from a standardized history, adhering as best we could to the criteria
of the American Thoracic Society. Patients reporting attacks of breathlessness and
wheeze (asthmatic attacks) without chronic (i.e. for more than 3 months per year) cough
or sputum production were identified as having asthma (31%). Current or former
smokers without a history of asthmatic attacks, reporting either chronic cough with or
without sputum production or dyspnea when walking quietly on level ground, or both,
were included in the COPD group (20%). Patients with both asthmatic attacks or
recurrent wheeze and chronic cough and sputum production were labelled asthmatic
bronchitics (31%). Subjects with insufficient data to establish a diagnosis from history
taking were included in an undefined diagnosis group (12%).
Atopy is an important parameter in the diagnostic work-up of patients with asthma and
COPD. Atopic status is routinely assessed by history taking and measurement of
objective parameters of atopy. The relative merits of these different parameters is only
partially known. In chapter 3, the relationships between allergic symptoms, allergy
parameters (skin test to house dust mite, total IgE, house dust mite specific IgE, and
blood eosinophil counts), and several confounding variables were assessed. Skin tests to
house dust mite proved to be better predictors for allergic symptoms than total or
specific IgE levels and eosinophil counts. The other allergy parameters gave no
additional information on symptoms once the skin test was known. Expressing the skin
test relative to the positive control was slightly better than the uncorrected wheal size
and cut-off values for a positive skin test are presented which are useful in both asthma
and COPD.
Chapter J I
The main results of the intervention trial are presented in chapter 4. The study was
terminated af\er 2.5 years instead of the 3 years that were originally planned, because of
predefined, large differences in drop-out rates and primary endpoints in favour of
patients treated with inhaled corticosteroids. The most striking result was the large
difference in withdrawal rates: almost 507o of patients who did not receive inhaled
corticosteroids withdrew from the study as compared to only 13%o of those who did
receive steroids. Sixty four percent of withdrawals were caused by deterioration of
clinical status in patients on bronchodilators only. In line with this, exacerbations rates
were approximately 0.75 per patient-year in both bronchodilator groups compared with
0.25 in the corticosteroid group. Airways obstruction, as measured by FEV,, improved
by lO%predicted in patients receiving steroids as compared to those who did not. This
difference was obtained within 3 months of therapy, to remain approximately stable
afterwards. Airways hypenesponsiveness, as measured by PCro, improved by 2.0
doubling doses in the group with steroids compared to no change in the other two
groups. The largest part of this improvement occurred during the first 6 months of
treatment, but afterwards airways hyperresponsiveness continued to decrease further.
Non-smokers, allergic patients, and patients younger than forty years benefitted more
from the addition of inhaled corticosteroids than smoking, non-allergic, and older
patients, but in all subgroups improvement occurred compared to the same subgroups
not receiving inhaled corticosteroids. No significant long-term differences were found
betr.veen patients receiving only a Br-agonist and those additionally receiving an
anticholinergic, even though acute bronchodilation was greater with ipratropium bromide
plus terbutaline than with terbutaline alone.
Airways hyperresponsiveness is the hallmark of asthma and it can also be demonstrated
in rnany patients with COPD. It has been suggested, however, that in patients with
COPD, airways hyperresponsiveness is closely related to the baseline FEV,, thus
implying that the increased responsiveness in COPD largely is an artifact. By contrast.
airrvays hyperresponsiveness in asthma is supposed to be largely determined by the
inflammatory process in the airway wall, and not by airway diameter. These differences
are challenged in chapter 5. For each level of prechallenge FEV,, patients with asthma
showed a lower PC.o value than patients with COPD. The dependence of PCro on
prechallenge FEV,, however, was comparable in all diagnosis groups. That a real
airways hyperresponsiveness can be found in patients with COPD is compatible with
clinical symptoms of increased breathlessness with cold air or fog found in many
patients with COPD.
The relationship of airways hyperresponsiveness to respiratory symptoms and peak flow
variation were found to be low cross-sectionally, suggesting that all these parameters
may provide different information on the actual disease state. No significant differences
were found between symptom based diagnosis groups with respect to diurnal peak flow
variation.
The effect of long-term treatment on the relationship between symptoms. airways
hyperresponsiveness, and diurnal peak flow variation was assessed longitudinally in
chapter 6. Morning peak flows increased markedly, as did afternoon peak flow to a
lesser extent. As a consequence, peak flow variability diminished with steroids. The
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within-subject, or longitudinal relationship of changes in peak flow variation with PCro
was found to be relatively weak; the relationships with changes in symptom scores,
FEV,, and bronchodilator response were even weaker. The results presented in this
chapter lend support to several international guidelines on asthma management that the
peak flow meter is a feasible and valuable instrument to follow lung function level at a
daily basis at home, but questions the measurement of peak flow variation as a proxy of
airways hyperresponsiveness.
Results of bronchodilator response tests are commonly used as a basis for disease
classification and choice of treatment by clinicians, and as an inclusion criterion for
studies by research workers. Despite these important functions of bronchodilator
response testing, there is no agreement on how to express the results. Four different
expressions of the bronchodilator response were compared cross-sectionally in chapter
7. Expressing the response relative to the baseline or initial value is the most commonly
used method, but it is demonstrated that this expression has the undesirable property of
being much more dependent on initial FEV, than for instance expressing the response
relative to the predicted FEV,. This latter expression had the highest likelihood of
separating patients with a symptom-based diagnosis of asthma from those with COPD.
Despite significant differences in mean response, large overlap of individual responses,
in whatever way expressed, occurred between diagnostic subgroups.
In chapter 8, the same four expressions of bronchodilator test results as in chapter 7
were examined longitudinally for 2.5 years. Changes during steroid and bronchodilator
therapy were evaluated, as well as long-term variability, and prognostic value of the
bronchodilator response in predicting response to inhaled corticosteroids. Bronchodilator
responses decreased substantially with inhaled corticosteroid therapy; this decrease could
only partially be explained by an increase in prebronchodilator lung function.
Bronchodilator responses were highly variable: as a result less than half of the patients
could consistently be classified as "reversible" or "irreversible". These data indicate that
decisions to label a patient's obstruction as "irreversible" should not be based on a
single bronchodilator test and should be made with taking the effects of anti-
inflammatory therapy into account. The bronchodilator response at the start of the study
proved to be a poor predictor of corticosteroid induced improvement in FEV, in the first
three months of treatment, when the changes in FEVt are most prominent.
Many patients with obstructive airways disease show improvement in FEV ' and PCro
during inhaled corticosteroid therapy, but the extent of the improvement varies
considerably between patients and studies. As it is unknown which patient characteristics
determine the differing response, we analyzed the independent influence of several
patient characteristics on improvement in FEV, and PCro during inhaled corticosteroids
in chapters 9 and 10, respectively. The more hyperresponsive patients, and
independently of that, the more allergic patients, and non-smoking patients showed a
larger improvement in FEV, during the first three months of inhaled corticosteroid
therapy than less hyperreactive, less allergic and smoking patients. Total IgE proved a
better independent predictor of this short-term response to corticosteroids than specific
IgE for house dust mite, skin tests, or blood eosinophils. A more favourable long-term
slope of FEV, after the first three months was predicted by a larger baseline
Chapter l1
bronchodilator response only. It was, however, impossible to predict from baseline
characteristics which individual patients would not show an improvement in FEV, at all.
Although age, FEV,, and bronchodilator response were all mono-variable predictors of
response in PC,,, to inhaled corticosteroids, in chapter l0 it is shown that only total
serum IgE is an independent predictor of response in PCro to steroids. Total serum IgE
proved to be a better independent predictor of changes in PC20 during corticosteroids
than other allergy parameters including house dust mite specific IgE, skin test for house
dust mite, sum of skin tests to 12 common aeroallergens, number of positive skin tests
(of l2), and blood eosinophil count.
Oral corticosteroids are known to be extremely powerful agents in many chronic
inflammatory diseases, amongst them obstructive airways disease. However, they
provoke serious side-effects, one of them being osteoporosis, leading to fractures.
Inhaled corticosteroids may be absorbed systemically. so since the introduction of
inhaled corticosteroids more than 20 years ago, there has been a constant watch for side
effects analogous to those of oral steroids. With the recent introduction of novel serum
parameters of bone metabolism, especially osteocalcin, renewed concern has arisen over
the effects of inhaled corticosteroids on bone turnover. In chapter 11 the effects of
inhaled corticosteroids on bone metabolism were monitored with several serum and
urinary parameters over 2.5 years of treatment. No clear-cut effect on bone formation or
resorption with inhaled corticosteroids was found.
Although the airways hyperresponsiveness i  a relatively well established risk factor for
obstructive airways disease is, the significance of asymptomatic airways
hyperresponsiveness i less clear. In a separate epidemiological study, described in
chapter 12, Borg dyspnoea scores were used to rate dyspnea before and after a
histamine challenge test. It was found that many asymptomatic hypenesponders do not
perceive the changes in airways obstruction as breathlessness.
Finally. our experience in setting up and conducting a long-term multi-centre trial is
discussed in chapter 13. It is stressed that prirnary and secondary end points should be
defined in advance. Our experience shows that it rnay be hard to recruit sufficient
numbers of patients for a long-term trial. A feasibility study is a useful tool in
implementing a standardized protocol and evaluating patient recruitment rates.
During the conduct of a long-term clinical trial. continuing quality control is of utmost
importance. Frequent interim analyses should be undertaken by an independent
committee on the basis of predefined end points and significance levels that are stricter
than those at the normal termination of a study. Ongoing motivation of patients and staff
is important to avoid trial fatigue.
14.2 Discussion
14.2.1 Limitations of the study
The patients entered in this study were selected in 6 hospitals. This implies that their
disease was severe enough to visit a pulmonary physician instead of their general
physician. It is also possible that a selection was introduced because of the fact that only
